Corporate News
LR Health & Beauty SE announces successful conclusion of the Written Procedure initiated on 6 March 2026 under the 2024/2028 Bonds and issuance of Super Senior Bonds
LR Health & Beauty SE announces successful conclusion of the Written Procedure initiated on 6 March 2026 under the 2024/2028 Bonds and issuance of Super Senior Bonds
Ahlen, 24 March 2026 – On 6 March 2026, LR Health & Beauty SE (the “Company”) initiated a written procedure (the “Written Procedure”) under the terms and conditions for the Company’s 2024/2028 bonds (ISIN: NO0013149658) (the “Bonds”) to implement certain amendments to, and request certain temporary waivers under, the terms and conditions for the Bonds in order to inter alia enable the incurrence of a super senior bridge financing in the form of a new bond in the amount of EUR 10,000,000 which will rank super senior in relation to the Bonds (the “Super Senior Bond”).
Deadline for voting in the Written Procedure was 15:00 hrs CET today. Votes representing a sufficient part of the adjusted nominal amount of the Bonds were obtained in order to form a quorum and a requisite majority of the adjusted nominal amount voted in favour of the amendments and the temporary waivers in the Written Procedure. Consequently, the amendments and the temporary waivers are effective immediately and the Company will issue the Super Senior Bond on or about 26 March 2026.
For further information regarding the Written Procedure, please refer to the notice of the Written Procedure which is accessible on the Company’s website at https://ir.lrworld.com/en/bond/.
LR Group
Under the motto “More quality for your life”, the LR Group – headquartered in the town of Ahlen/Westphalia – successfully produces and distributes various high-quality nutritional supplements and cosmetic products in 32 countries. As an attractive Social Commerce Company, LR supports the personal exchange in its community with efficient, digital solutions. The holistic tool “LR neo” offers the international partnership all business-relevant key figures and information for their LR business in one dashboard.
Since 1985, LR has been firmly established in the market as a “people business” with a focus on people and personal consultation. In times of changing working environments, the business model is particularly appealing to those who are looking for more flexibility, a better work-life balance and greater financial independence.
The processing of aloe vera has been one of LR’s core competencies for over 20 years. Only the leaf’s valuable inside is used for the products. In Ahlen, the company has built one of the most modern aloe vera production facilities for aloe vera drinking gels in Europe.
In the fall of 2009, LR founded the LR Global Kids Fund e.V., which supports disadvantaged children and their families in many countries around the world efficiently and without the usual red tape in cooperation with local institutions. For further information on our commitment to sustainability, please read our Sustainability Report.
Contact:
PR Contact:
LR Health & Beauty SE
Almut Kellermeyer
Head of Corporate Communication
Kruppstraße 55
59227 Ahlen
Phone: +49(0)2382 7658-106
E-mail: a.kellermeyer@LRworld.com
https://ir.lrworld.com/
IR Contact:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Building D
65195 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-mail: burbach@cometis.de
LR Health & Beauty SE advances strategic realignment
LR Health & Beauty SE advances strategic realignment
- Strategic initiatives over the course of 2026 to provide tangible impetus for partners’ business activities
- Initiatives supported by financially strong investors
Ahlen, 6 March 2026 – LR Health & Beauty SE, Europe’s leading social commerce company in the area of high-quality health and beauty products, is taking the next step in its financial realignment. To this end, the Company today entered into further agreements that enable the company to implement targeted strategic initiatives for a sustainable positive business development.
Jörg Körfer, Chief Executive Officer (CEO) of LR Health & Beauty SE, explains: “The injection of fresh capital will advance our strategic realignment. In this respect, we are pleased to have financially strong partners at our side which secure and strengthen LR’s long-term financial stability and investment capacity. This will create the conditions for launching further targeted strategic initiatives in 2026. In April, our Business Days will be held with several thousand distribution partners. We will take this opportunity to present a promising product launch in the health and beauty area and further advance business with our partners. We will also inform our partner community about exciting news regarding our sales competitions and the LR car concept with the latter receiving its own showroom where partners will be able to celebrate the car handover in the future.”
In order to align business processes with future growth, LR is focusing, among other things, on inhouse production of selected products and efficiency enhancements through greater vertical integration. Accordingly, preparations are under way for the in-house production of an attractive top-selling product from the portfolio in order to benefit from improved scalability and flexibility. The project launched for this purpose is supported by the German Federal Ministry of Research, Technology and Space (BSFZ). The BSFZ supports projects that demonstrate a high level of entrepreneurial innovation capability.
LR Group
Under the motto “More quality for your life”, the LR Group – headquartered in the town of Ahlen/Westphalia – successfully produces and distributes various high-quality nutritional supplements and cosmetic products in 32 countries. As an attractive Social Commerce Company, LR supports the personal exchange in its community with efficient, digital solutions. The holistic tool “LR neo” offers the international partnership all business-relevant key figures and information for their LR business in one dashboard.
Since 1985, LR has been firmly established in the market as a “people business” with a focus on people and personal consultation. In times of changing working environments, the business model is particularly appealing to those who are looking for more flexibility, a better work-life balance and greater financial independence.
The processing of aloe vera has been one of LR’s core competencies for over 20 years. Only the leaf’s valuable inside is used for the products. In Ahlen, the company has built one of the most modern aloe vera production facilities for aloe vera drinking gels in Europe.
In the fall of 2009, LR founded the LR Global Kids Fund e.V., which supports disadvantaged children and their families in many countries around the world efficiently and without the usual red tape in cooperation with local institutions. For further information on our commitment to sustainability, please read our Sustainability Report.
Contact:
PR Contact:
LR Health & Beauty SE
Almut Kellermeyer
Head of Corporate Communication
Kruppstraße 55
59227 Ahlen
Phone: +49(0)2382 7658-106
E-mail: a.kellermeyer@LRworld.com
https://ir.lrworld.com/
IR Contact:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Building D
65195 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-mail: burbach@cometis.de
LR Health & Beauty SE publishes Q4 2025 report and advances financial and strategic initiatives
LR Health & Beauty SE publishes Q4 2025 report and advances financial and strategic initiatives
- FY 2025 sales reached EUR 277.1 million on a preliminary basis, with EBITDA reported of EUR 16.5 million
- Focus on implementing a new financing structure and initiating targeted strategic measures for long-term business development and growth
- Planned launch of new generation of products combining health and beauty expertise demonstrates innovative strength and sets important impulses for 2026
Ahlen, 24 February 2026 – LR Health & Beauty SE, Europe’s leading digital social commerce company for high-quality nutritional supplements and beauty products, today publishes its results for the fourth quarter of 2025 as well as preliminary sales and earnings results for the 2025 financial year.
The LR Group continued to face generally subdued consumer sentiment in Western European markets in the fourth quarter of 2025. LR Health & Beauty SE achieved sales (revenue from goods sold) of EUR 68.2 million in the fourth quarter 2025 (Q4 2024: EUR 76.5 million), representing a decrease of 10.9%. Accordingly, over the course of the full 2025 year, LR Health & Beauty SE posted a 4.6% year-on-year lower level of sales of EUR 277.1 million on a preliminary basis (2024: EUR 289.2 million).
Furthermore, LR Health & Beauty SE achieved EBITDA reported of EUR 0.3 million in the fourth quarter of 2025 (Q4 2024: EUR 8.3 million). The results in the final quarter were particularly affected by the lower sales level and exceptional items as part of the realignment of the financing structure. For the full 2025 year, reported EBITDA on a preliminary basis amounted to EUR 16.5 million compared with EUR 27.3 million in 2024. Normalized EBITDA in the fourth quarter of 2025 decreased to EUR 3.4 million, compared with EUR 9.5 million in the fourth quarter of the previous year. Accordingly, over the full course of 2025, normalized EBITDA amounted to EUR 22.5 million on the basis of preliminary figures (2024: EUR 32.6 million).
Jörg Körfer, CEO of LR Health & Beauty SE, comments: “In both financial and strategic terms, we are focusing consistently on creating the preconditions for sustainably positive business growth. We have recently reached an important milestone with the agreement concerning a realignment of the financing structure. At the same time, it is important in 2026 to advance the LR Group’s business with suitable strategic initiatives. One focus in this context is the further development of our product portfolio. In the spring, we are planning the promising launch of a new generation of products that combines expertise from the health and beauty areas and will provide our distribution partners with fresh impetus for their business activities.”
In developing high-quality dietary supplements and cosmetic products, LR regularly draws on the latest findings from science and research. Sustainability aspects are also given special consideration when optimising the product portfolio – including in the upcoming product launch.
The report for the fourth quarter of 2025 is available online from today on the company’s website at https://ir.lrworld.com/. The final, audited results for the 2025 financial year will be published at the end of April 2026 with the Annual Report on the company’s website.
LR Group
Under the motto “More quality for your life”, the LR Group – headquartered in the town of Ahlen/Westphalia – successfully produces and distributes various high-quality nutritional supplements and cosmetic products in 32 countries. As an attractive Social Commerce Company, LR supports the personal exchange in its community with efficient, digital solutions. The holistic tool “LR neo” offers the international partnership all business-relevant key figures and information for their LR business in one dashboard.
Since 1985, LR has been firmly established in the market as a “people business” with a focus on people and personal consultation. In times of changing working environments, the business model is particularly appealing to those who are looking for more flexibility, a better work-life balance and greater financial independence.
The processing of aloe vera has been one of LR’s core competencies for over 20 years. Only the leaf’s valuable inside is used for the products. In Ahlen, the company has built one of the most modern aloe vera production facilities for aloe vera drinking gels in Europe.
In the fall of 2009, LR founded the LR Global Kids Fund e.V., which supports disadvantaged children and their families in many countries around the world efficiently and without the usual red tape in cooperation with local institutions. For further information on our commitment to sustainability, please read our Sustainability Report.
Contact:
PR Contact:
LR Health & Beauty SE
Almut Kellermeyer
Head of Corporate Communication
Kruppstraße 55
59227 Ahlen
Phone: +49(0)2382 7658-106
E-mail: a.kellermeyer@LRworld.com
https://ir.lrworld.com/
IR Contact:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Building D
65195 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-mail: burbach@cometis.de
Ad-hoc Announcements
LR HEALTH & BEAUTY SE INITIATES A WRITTEN PROCEDURE UNDER ITS OUTSTANDING BOND LOAN IN RESPECT OF TEMPORARY WAIVERS AND SUPER SENIOR BRIDGE FINANCING
Disclosure of an inside information according to Art. 17 of the Regulation (EU) No. 596/2014 (Market Abuse Regulation – MAR)
LR HEALTH & BEAUTY SE INITIATES A WRITTEN PROCEDURE UNDER ITS OUTSTANDING BOND LOAN IN RESPECT OF TEMPORARY WAIVERS AND SUPER SENIOR BRIDGE FINANCING
Ahlen, 6 March 2026 – LR Health & Beauty SE (the “Company”) has, as of today, entered into further agreements with holders of the Company’s 2024/2028 bonds (ISIN: NO0013149658) (the “Bondholders” and the “Bonds”) representing more than two thirds (2/3) of the nominal amount of the Bonds (the “Majority Bondholders”) and the Company's shareholder regarding a comprehensive restructuring of the Bonds and the Company’s capital structure (the “Restructuring”).
A comprehensive restructuring, such as the Restructuring, will take time to implement which means that the Company will be in need of bridge financing in an amount of EUR 10,000,000 until the Restructuring is implemented. Certain Bondholders have undertaken to provide a bridge financing in the amount of EUR 10,000,000, having a super senior ranking in relation to the Bonds (the "Super Senior Bridge Financing"). The Super Senior Bridge Financing is intended to be refinanced in connection with closing of the Restructuring. Such Super Senior Bridge Financing may or may not share the security and guarantee package of the Bonds under an intercreditor agreement (in part or in full) and may further benefit from certain Super Senior Bridge Financing only share security.
In addition, the Majority Bondholders agreed to further extend the standstill undertaking comprising, inter alia, that Bondholders shall not derive any rights from breaches of the maintenance test (including the leverage covenant) or from any non-payments of interest until end of June 2026 (subject to extension).
In light of the above, the Company has today initiated a written procedure (the “Written Procedure”) under the Bonds to implement the above by way of amendments to and temporary waivers under the terms and conditions for the Bonds.
The notice of the Written Procedure and further details are accessible on the Company’s website at https://ir.lrworld.com/en/bond/.
IR contact:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Gebäude D
65195 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-mail: burbach@cometis.de
End of inside information
LR HEALTH & BEAUTY SE REACHES AN AGREEMENT WITH BONDHOLDERS AND SHAREHOLDER REGARDING A COMPREHENSIVE RESTRUCTURING OF THE 2024/2028 BOND – EUR 20 MILLION IN NEW CAPITAL AND SIGNIFICANTLY REDUCED DEBT STRUCTURE
Disclosure of an inside information according to Art. 17 of the Regulation (EU) No. 596/2014 (Market Abuse Regulation – MAR)
LR HEALTH & BEAUTY SE REACHES AN AGREEMENT WITH BONDHOLDERS AND SHAREHOLDER REGARDING A COMPREHENSIVE RESTRUCTURING OF THE 2024/2028 BOND – EUR 20 MILLION IN NEW CAPITAL AND SIGNIFICANTLY REDUCED DEBT STRUCTURE
Ahlen, 11 February 2026 – Today, LR Health & Beauty SE (the “Company”) reached an agreement with bondholders representing more than two thirds (2/3) of the nominal amount of the Company’s outstanding 2024/2028 bonds (ISIN: NO0013149658) (the “Bonds”) as well as the Company’s shareholder regarding a comprehensive restructuring of the Bonds and the Company’s capital structure.
The restructuring comprises an aggregate equity and debt injection of EUR 20 million in new capital, consisting of a (i) EUR 10 million equity contribution and (ii) EUR 10 million in New Money Senior Bonds (as defined below). The shareholder Evoco will continue its commitment to the Company demonstrating confidence and support to the Company.
The Company’s debt structure will be significantly downsized and restructured as follows:
- Senior secured debt of EUR 62.5 million comprising of the following tranches which will rank pari passu with each other and carry a fixed cash interest of 6.75% per annum:
- EUR 10 million new money senior bonds (the “New Money Senior Bonds”), to be subscribed for in cash by bondholders (offered pro rata to all bondholders). The New Money Senior Bond issue will be fully backstopped by certain major bondholders.
- EUR 20 million reinstated elevated bonds (the “Reinstated Elevated Bonds”), allocated pro rata to bondholders who participate in the New Money Senior Bonds.
- EUR 32.5 million reinstated bonds (the “Reinstated Bonds”), allocated pro rata to all existing bondholders.
- Unsecured subordinated junior bonds of EUR 27.5 million (the “Junior Bonds”), allocated pro rata to all existing bondholders, with payment-in-kind interest stepping up linearly from 6% per annum year one to 10% per annum year five, maturing in 2031.
- The part of the nominal amount of the Bonds (including accrued interest thereunder) that is not reinstated into Reinstated Elevated Bonds, Reinstated Bonds or Junior Bonds shall be written off in its entirety.
The agreement is set out in a lock-up agreement entered into between the Company, its shareholder and bondholders representing more than two thirds (2/3) of the nominal amount for the Bonds, whereunder inter alia the parties have undertaken to implement the comprehensive restructuring and the bondholders have agreed to not accelerate the Bonds during the lock-up period (ending 30 April 2026). Implementation of the restructuring is subject to approval by bondholders in one or several written procedures and by formal shareholder approval, and shall be completed by the end of the lock-up period.
IR contact:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Gebäude D
65195 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-mail: burbach@cometis.de
End of inside information
LR HEALTH & BEAUTY SE: PRELIMINARY RESULTS FOR FINANCIAL YEAR 2025 / TARGETED EQUITY CONTRIBUTION / TARGETED RESTRUCTURING OF THE 2024/2028 BONDS
Disclosure of an inside information according to Art. 17 of the Regulation (EU) No. 596/2014 (Market Abuse Regulation – MAR)
LR HEALTH & BEAUTY SE: PRELIMINARY RESULTS FOR FINANCIAL YEAR 2025 / TARGETED EQUITY CONTRIBUTION / TARGETED RESTRUCTURING OF THE 2024/2028 BONDS
Ahlen, 23 January 2026 – Today, based on the preliminary financial results for the financial year 2025, the Management Board of LR Health & Beauty SE (the “Company”) expects an EBITDA* reported of around EUR 16 million for the financial year 2025 (previously expected to be between EUR 17.0 million and EUR 20.0 million). At the same time, the Management Board of the Company expects sales (revenue from goods sold) of around EUR 277 million for the full year 2025 (previously expected to be between EUR 276 million and EUR 281 million).
Also today, EY-Parthenon announced the completion of a draft IDW S 6 restructuring opinion in respect of the Company. Pursuant to the analysis set out in that draft restructuring opinion, the Company will for the financial year 2028 achieve an EBITDA* of EUR 27.3 million and sales of EUR 281.5 million in the sensitivity case, and an EBITDA* of EUR 31.4 million as well as sales of EUR 284.7 million in the management case.
Against this background, the Company decided today to enter into discussions with its shareholder and with the bondholders of the Company’s outstanding 2024/2028 bonds (ISIN: NO0013149658) (the “Bonds”). The aim of such discussions is to explore the possibility of a financial restructuring of the Company comprising (the following measures together the “Restructuring Measures”):
- an equity contribution from the Company’s shareholder in the amount of EUR 10 million for financing of the Company’s operating business; and
- bondholder approval of certain amendments to the terms and conditions of the Bonds (through a new written procedure under the Bonds) in respect of:
- a write-down of 55 % of the nominal amount of the Bonds on a pro rata basis (including the capitalised interest in respect of the interest payments under the Bonds due in November 2025 and February 2026), after which the outstanding nominal amount under the Bonds will amount to EUR 61.3 million;
- an extension of the term of the Bonds until 31 December 2029;
- a deferral of the interest payments under the Bonds due in November 2025 and February 2026 (on a capitalising basis and subject to write-down mechanism set out above) and other interest payments under the Bonds due during the period up to and including May 2027 (on a capitalising basis) until the Bonds’ extended maturity date;
- cash sweep mechanisms for excess cash over a EUR 15 million threshold; and
- a contractual right (Besserungsschein) for the bondholders to receive cash in an aggregate amount of up to EUR 74.9 million (being equal to the written down amount) out of any excess cash received out of a refinancing of the Bonds.
The holders of the Bonds shall be entitled to participate in the refinancing process.
If the Restructuring Measures cannot be implemented, it is currently assumed that the holders of the Bond could expect an insolvency quota of around 6% in an insolvency liquidation scenario.
IR contact:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Gebäude D
65195 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-mail: burbach@cometis.de
*EBITDA, based on IFRS as used in the unaudited consolidated interim report of the Company for Q3 2025 which can be found on the Company’s website at https://media.lrworld.com/IR/Interim_Report_Q3_2025.pdf.
End of inside information
Directors‘ Dealings
At the moment no news are available.